Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Columnist Kylene Henderson's husband, Donnie, had to pivot in many aspects of life due to PF, including changing his career.

A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...

Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to ...

Cautionary Language Concerning Forward-Looking Statements ...

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA, ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.